Belite Bio, Inc.

Against a background of the globally strengthening R&D focus on rare diseases, Japan is seeing unusually fierce competition in the relatively small indication of Stargardt disease, a rare ophthalmolog

Astellas Pharma, Inc. has entered into a definitive agreement to acquire US bioventure Iveric Bio for a total equity value of approximately $5.9bn, in a bid to enhance the Japanese major’s strategi

It has been a miserable year for biotechs who were planning to hit the markets for funds, and initial public offerings are at their lowest for a decade, but Spain's Oryzon Genomics SA is going again

"Tulip mania" was the first documented major economic bubble and also one of the most famous market crashes. It happened during the seventeenth century in Holland when speculators sent prices of tulip